Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > New Press Release - Theratechnologies Announces Amendments to its Term Loan Facility With Affiliates of Marathon Asset Management

<< Previous

Bullboard Posts

Next >>

Comment by archeo753on Jul 28, 2023 5:36pm

157 Views

Post# 35562443

RE:RE:New Press Release - Theratechnologies Announces Amendments to its Term Loan Facility With Affiliates of Marathon Asset Management

Is the ATM still active? Can they just sell shares as needed to achieve the minimum $ amount if they get close to the $15 million in the next 90 days. Obviously would be very bad for current shareholders to sell equity at current prices. A partnership would definitely be preferable.

SPCEO1 wrote: That is excellent news and the stock should make up a lot of its recent lost ground as a result.

Worth noting:

No interest penalty applied

no warrants issued

October 31st date could mean this is when they should move into a cash flow positive situation or they may have signed a partnership deal by then or they may have some early data they share with the market and use that to raise some cash.

Marathon seems like it is looking forward to making a lot of money on those warrants and they have treated THTX easily. They are clearly no acting like cut-throat lenders.

PressRelease wrote:
Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023 This news release constitutes a designated news release for the purposes of the Companys prospectus supplement dated December 16, 2021 to its short form base shelf prospectus...read article.